


SHORT REPORT

Open Access



# Degradation of endogenous proteins and generation of a null-like phenotype in zebrafish using Trim-Away technology

Xiao Chen<sup>1†</sup>, Mi Liu<sup>1†</sup>, Hongyan Lou<sup>2†</sup>, Yiyi Lu<sup>3</sup>, Meng-Tao Zhou<sup>1</sup>, Rongying Ou<sup>2</sup>, Yunsheng Xu<sup>3</sup> and Kai-Fu Tang<sup>1\*</sup> 

## Abstract

Trim-Away is a recent technique to rapidly deplete a protein from any cell type. Guided by antibodies, TRIM21 selects proteins for destruction. However, the applicability of this method in model organisms has not been investigated. Here, we show that Trim-Away can degrade proteins in zebrafish embryos. Trim-Away depletes proteins faster than morpholinos, which enables analysis of protein function during early embryogenesis. Furthermore, Trim-Away can be applied to evaluate the role of maternally contributed proteins in zebrafish embryos. Our findings indicate that Trim-Away is a powerful tool to perform functional analysis of proteins during zebrafish development.

**Keywords:** TRIM21, Trim-away, Protein degradation, Knockdown

## Background

Loss of function by genomic DNA modification or mRNA targeting is a widely used strategy to investigate gene function [1–5]. TRIM21 is an E3 ubiquitin ligase that binds with high affinity to the Fc domain of antibodies and recruits the ubiquitin-proteasome system to degrade targeted proteins [6–8]. The Trim-Away technique was recently developed to directly degrade endogenous proteins in cultured cells using anti-target antibodies and TRIM21 [9]. Unlike DNA- or RNA-targeting methods, which take hours or days to deplete proteins of interest, the Trim-Away system removes endogenous proteins within minutes [9]. However, the application of Trim-Away in model organisms has not been reported.

## Results and discussion

To determine whether the Trim-Away technique can be used to degrade proteins in zebrafish embryos *in vivo*, we developed transgenic zebrafish transiently expressing

enhanced green fluorescent protein (EGFP) by injecting an EGFP expression plasmid into the embryo yolks at 0 h postfertilization (hpf). The human TRIM21 recombinant protein and an anti-EGFP antibody were then injected into the yolks of EGFP-expressing embryos at 24 hpf. EGFP was rapidly degraded following injection, with a half-life of 16 min (Additional file 1: Figure S1a-c). Interestingly, TRIM21 and anti-EGFP antibody were degraded concomitantly (Additional file 1: Figure S1c). EGFP expression gradually recovered when TRIM21 and anti-EGFP antibody were completely degraded (Additional file 1: Figure S1a-c). Trim-Away-induced EGFP degradation was dependent on the dose of TRIM21 and anti-EGFP antibody (Additional file 1: Figure S1d, e). Treatment with the proteasome inhibitor MG132 prevented EGFP degradation following co-injection of anti-EGFP antibody and TRIM21 (Additional file 1: Figure S1f, g), indicating proteasome-dependent degradation of target proteins in zebrafish triggered by Trim-Away. We then evaluated whether Trim-Away could be used to degrade endogenous zebrafish proteins by targeting Ddx19B, a protein essential for mRNA export, translation, and genome stability [10–12]. Injection of TRIM21 and an anti-Ddx19B antibody into the embryo yolks at 0 hpf caused Ddx19B downregulation 1 h after injection (Fig. 1a). All TRIM21/anti-Ddx19B-injected

\* Correspondence: [tang\\_kaifu@wmu.edu.cn](mailto:tang_kaifu@wmu.edu.cn); [tangkaifu@hotmail.com](mailto:tangkaifu@hotmail.com)

<sup>†</sup>Xiao Chen, Mi Liu and Hongyan Lou contributed equally to this work.

<sup>1</sup>Key Laboratory of Diagnosis and Treatment of Severe Hepato-Pancreatic Diseases of Zhejiang Province, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325015, Zhejiang, People's Republic of China  
Full list of author information is available at the end of the article






Fig. 1 (See legend on next page.)

(See figure on previous page.)

**Fig. 1** Comparing the effects of Ddx19B or Dicer1 knockdown by Trim-Away or morpholinos in zebrafish embryos. Zebrafish embryos were co-injected with TRIM21 and antibodies (anti-Ddx19B antibody, anti-Dicer1 antibody, or control IgG) or injected with morpholinos (*ddx19b*-MO, *Dicer1*-MO, or Con-MO) at 0 hpf. **a** The level of Ddx19B or Dicer1 was determined by western blotting at the indicated time points. **b** Lateral view of eye size at the indicated time points. **c** Lateral view of the body axis at 2 dpf. **d** Eye diameter in embryos injected with different doses of TRIM21/anti-Ddx19B antibody or TRIM21/IgG was measured at the indicated time points; zebrafish numbers are indicated in brackets. **e** The level of miR-26a and let-7a was determined at the indicated time points. **f** Lateral view of embryos at the indicated time points. The data in **d** and **e** are shown as the mean  $\pm$  SD of three independent experiments, \* $P \leq 0.05$ , \*\* $P \leq 0.01$ , NS indicates  $P > 0.05$


zebrafish had small eyes, and about 10% had a curved body axis (Fig. 1b, c), consistent with the findings in homozygous *ddx19b*-mutant (*ddx19b*<sup>hi1464/hi1464</sup>) zebrafish [13]. The reduction in eye size was most obvious during the first 2–3 days postfertilization (dpf) but gradually recovered with time and was completely restored at 5 dpf (Fig. 1b, d). The reduction in eye size was dependent on the dose of TRIM21 and anti-Ddx19B antibody (Fig. 1d). However, injection of TRIM21 and anti-Ddx19B antibody at 2 hpf or later failed to induce these morphological defects, although Ddx19B expression was still downregulated 1 h after injection (Additional file 1: Figure S2a, b). Given that Ddx19B expression was high during the first 2 h after fertilization and then gradually decreased (Additional file 1: Figure S2c, d), we proposed that Ddx19B is essential in the first 2–3 h of embryogenesis but dispensable in the late embryonic development. Morpholinos are a class of short antisense oligonucleotides widely used to knockdown gene expression in zebrafish by blocking splicing or translation of specific mRNA, thereby taking hours or days to deplete target proteins [5, 14, 15]. Microinjection of *ddx19b*-MO into the zebrafish embryo yolks at 0 hpf significantly downregulated Ddx19B expression at 24 hpf, but not at 6 hpf (Fig. 1a). Furthermore, *ddx19b*-MO failed to cause morphological defects such as small eyes and curved body axis (Fig. 1b, c). These findings indicate that morpholinos are not suitable to investigate the function of *ddx19b* because they cannot deplete Ddx19B fast enough to completely block its functional activity.

Dicer1 is a key component of the RNA interference pathway and is essential for miRNA biogenesis [16]. Although *Dicer1* mutant zebrafish retain pre-miRNA processing activity for up to 10 dpf and have no obvious defects other than the developmental delay at 7–10 dpf, morpholino-mediated Dicer1 downregulation in zebrafish causes developmental arrest at 2 dpf, indicating the importance of maternal *Dicer1* mRNA in embryogenesis [17]. Moreover, maternal-zygotic *Dicer1* mutants display earlier and more severe morphological defects than *Dicer1* morpholino-treated zebrafish [17, 18], suggesting that maternal Dicer1 protein regulates early embryogenesis. Injection of TRIM21 and an anti-Dicer1 antibody into the zebrafish yolks at 0 hpf caused faster downregulation of Dicer1 protein, earlier deregulation of pre-miRNA processing activity, and earlier and more

severe morphogenesis defects compared to *Dicer1* morpholinos (Fig. 1a, e, f). Dicer1 Trim-Away zebrafish started dying at 2–3 dpf, and none were alive after 4 dpf. These data suggest that maternally contributed Dicer1 protein is essential for early embryogenesis. Our findings indicate that Trim-Away enables functional analysis of maternally contributed proteins, which are difficult to study using DNA- or RNA-targeting methods.

It has been reported that TRIM21, anti-target antibodies, and target proteins are all degraded during the Trim-Away process [9]. Consistently, we found that TRIM21 and anti-EGFP antibody were rapidly degraded after co-injection into the yolks of zebrafish embryos that express EGFP (Fig. 2a). However, they degraded more slowly after co-injection into the yolks of embryos that did not express EGFP (Fig. 2a), suggesting that the injected TRIM21 and anti-target antibodies can be stored in the embryos in the absence of the target protein. Genetic manipulation in zebrafish is usually performed by microinjection at early stage embryos. Therefore, we assessed whether co-injection of TRIM21 and anti-target antibody into one-cell embryos could degrade proteins expressed several hours later. After injection of an EGFP expression plasmid into one-cell embryos, EGFP expression was detected at 6 hpf; however, co-injection with TRIM21/anti-EGFP antibody delayed the EGFP expression until 16 hpf (Additional file 1: Figure S3).

Next, we examined whether Trim-Away could be used to delay the expression of endogenous zebrafish proteins. Microphthalmia-associated transcription factor a (*Mitfa*) is a basic helix-loop-helix/leucine zipper transcription factor required for neural crest-derived melanocyte development [19, 20], and homozygous *mitfa* mutants lack melanophore pigmentation throughout the embryonic and larval development [19]. Consistent with the previous findings [19, 20], *Mitfa* expression in zebrafish started at 18 hpf (Fig. 2b). The degradation of injected TRIM21 and anti-*Mitfa* antibody was slow before *Mitfa* expression but significantly accelerated afterwards (Fig. 2c). Moreover, injection of TRIM21 and anti-*Mitfa* antibody into one-cell embryos delayed *Mitfa* expression until 24 hpf and led to slight and temporary pigmentation defects (Fig. 2d, e). Transient *Mitfa* knockdown using the Trim-Away technology did not produce



**Fig. 2** Degradation of Mitfa occurs 18 h after injection of TRIM21 and anti-Mitfa antibody. **a** EGFP expression plasmid or control pcDNA3.1 plasmid was injected into one-cell embryos. TRIM21 and anti-EGFP antibody were then co-injected into EGFP-expressing embryos or pcDNA3.1 plasmid-injected embryos at 24 hpf. The levels of EGFP, anti-EGFP antibody, and TRIM21 were analyzed by western blotting at different time points. **b** Mitfa expression in zebrafish embryos was determined at different time points by western blotting. **c** One-cell embryos were co-injected with TRIM21 and an anti-Mitfa antibody or nonspecific IgG and analyzed for the levels of Mitfa, TRIM21, and IgG heavy chain at different time points by western blotting. **d, e** One-cell zebrafish embryos were injected with *mitfa* morpholinos (*mitfa*-MO) or control morpholinos (Con-MO) or co-injected with TRIM21/anti-Mitfa antibody or TRIM21/nonspecific IgG. Mitfa knockdown was confirmed at 22 hpf by western blotting; the arrow indicates IgG heavy chain (**d**). Lateral view of the embryos at different time points; embryos treated with *N*-phenylthiourea (PTU) were used as positive controls (**e**)

long-term effects since the embryos were able to develop into fertile adult zebrafish without gross abnormalities. In agreement with the previous findings [21, 22], *mitfa*-MO induced more profound pigmentation defects than Trim-Away (Fig. 2e).

Methionine sulfoxide reductase B3 (*Msrb3*) catalyzes the reduction of methionine sulfoxide to methionine. Homozygous mutations of the *Msrb3* gene are associated with human deafness [23], and *Msrb3* knockout caused profound hearing loss by inducing degeneration of stereocilia hair cells [24], whereas morpholino-induced *Msrb3* knockdown compromised otolith development [25]. Therefore, we investigated whether Trim-Away could be used to analyze *Msrb3* function. *Msrb3* expression started at 15 hpf (Additional file 1: Figure S4a). Injection of TRIM21 and an anti-*Msrb3* antibody into one-cell embryos decreased the *Msrb3* expression at 18 hpf and resulted in abnormal numbers of otoliths, which were tiny and/or fused (Additional file 1: Figure S4b, c). Thus, injection of TRIM21 together with anti-target antibody into one-cell embryos can degrade proteins produced several hours later. This suggests that, in addition to degradation of disease-causing proteins, Trim-Away could be used to prevent their expression.

We next confirmed the specificity of the Trim-Away system in zebrafish. First, in a plasmid rescue assay, co-injection of a *Mitfa* expression plasmid with TRIM21/anti-*Mitfa* antibody completely restored the pigmentation phenotype (Additional file 1: Figure S5a, b). Second, injection of TRIM21 with two antibodies against different regions of *Ddx19B* or *Dicer1* caused target protein degradation and produced similar phenotypic defects (Additional file 1: Figure S5c-f). Third, injection of TRIM21 alone or together with a control IgG did not affect the expression of EGFP, *Ddx19B*, *Dicer1*, *Mitfa*, and *Msrb3* and failed to induce morphological abnormalities (Figs. 1 and 2c-e; Additional file 1: Figure S1a-1e, S2a-b, and S3, S4b-c, S5, S6, S8). Finally, injection of anti-target antibodies alone did not induce target protein degradation and phenotypic defects (Additional file 1: Figure S1a, S3a, and S7). However, these data do not rule out nonspecific effects, especially for the pleiotropic phenotypes of *Ddx19B* and *Dicer1* Trim-Away embryos. To clarify pleiotropic or nonspecific effects, transcriptome analysis should be performed to compare gene expression in Trim-Away embryos with that in zygotic or maternal-zygotic mutants.

Two technical points should be considered. First, although injection of TRIM21/target antibody into either cells or yolks led to target protein degradation and caused similar phenotypic defects (Additional file 1: Figure S8), yolk injection is much easier to perform. Second, although Trim-Away induced dose-dependent degradation of EGFP and reduction of the eye size in the range of 0.5–2 ng of TRIM21 and anti-target antibodies

(mixed 1:1) per embryo, dose elevation from 1 to 2 ng only slightly augmented EGFP degradation and eye size reduction and that from 2 to 4 ng did not cause further enhancement (Fig. 1d; Additional file 1: Figure S1d, e). Therefore, injection of 1 ng TRIM21 and 1 ng of antibody into the zebrafish yolks is recommended. However, given that *Mitfa* overexpression seems to overwhelm the effect of TRIM21/antibodies injected (Additional file 1: Figure S5a, b), more TRIM21/antibodies should be used when the targeted proteins are highly abundant.

## Conclusions

We demonstrated that Trim-Away can be used to investigate protein function during the first few hours of zebrafish embryogenesis. In contrast, morpholinos take hours or days to deplete target proteins and thus are not suitable to investigate protein function in early embryogenesis. Moreover, Trim-Away enables functional analysis of maternally contributed proteins, as well as proteins expressed several hours after injection of TRIM21/anti-target antibody into one-cell embryos. Therefore, Trim-Away is a powerful tool to determine protein functions during zebrafish development.

## Methods

Mixtures of recombinant TRIM21 and anti-target antibody were directly injected into the yolks or cells of zebrafish embryos. Gene expression levels were determined by western blotting or real-time RT-PCR. Two-tailed Student's *t* tests were performed to evaluate the statistical significance of the results. Detailed methods are available in Additional file 1. All full-length western blots are available in Additional file 2.

## Additional files

**Additional file 1:** Contains supplementary methods, supplementary tables, and eight supplementary figures with legends. (PDF 1250 kb)

**Additional file 2:** Contains all full-length western blot images. (PDF 720 kb)

**Additional file 3:** Review history. (DOCX 744 kb)

## Abbreviations

dpf: Days postfertilization; EGFP: Enhanced green fluorescent protein; hpf: Hours postfertilization; *Mitfa*: Microphthalmia-associated transcription factor a; *Msrb3*: Methionine sulfoxide reductase B3; PTU: *N*-phenylthiourea

## Acknowledgements

The authors wish to thank Zhechao Zhang and Lina Zou for technical assistance.

## Review history

The review history is included in Additional file 3.

## Funding

This work was supported by the National Natural Science Foundation of China (grant numbers: 81572780 and 81773011) and Natural Science Foundation of Zhejiang Province (grant numbers: LZ16H160004 and LY16C050004).

**Availability of data and materials**

Not applicable

**Authors' contributions**

KFT designed the study. XC, HL, and ML carried out the experiments. KFT, XC, HL, ML, YL, ZMT, RO, and YX interpreted the results. KFT wrote the manuscript. All authors read and approved the final manuscript.

**Ethics approval and consent to participate**

All zebrafish were reared and handled in accordance with the Institutional Guidelines on Animal Usage and Maintenance of Wenzhou Medical University.

**Consent for publication**

Not applicable

**Competing interests**

The authors declare that they have no competing interests.

**Publisher's Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Author details**

- <sup>1</sup>Key Laboratory of Diagnosis and Treatment of Severe Hepato-Pancreatic Diseases of Zhejiang Province, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325015, Zhejiang, People's Republic of China.  
<sup>2</sup>Department of Gynecology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325015, Zhejiang, People's Republic of China.  
<sup>3</sup>Department of Dermato-Venereology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325015, Zhejiang, People's Republic of China.

Received: 1 July 2018 Accepted: 8 January 2019

Published online: 23 January 2019

**References**

- Thompson S, Clarke AR, Pow AM, Hooper ML, Melton DW. Germ line transmission and expression of a corrected HPRT gene produced by gene targeting in embryonic stem cells. *Cell*. 1989;56:313–21.
- Wright DA, Li T, Yang B, Spalding MH. TALEN-mediated genome editing: prospects and perspectives. *Biochem J*. 2014;462:15–24.
- Doudna JA, Charpentier E. Genome editing. The new frontier of genome engineering with CRISPR-Cas9. *Science*. 2014;346:1258096.
- Hannon GJ, Rossi JJ. Unlocking the potential of the human genome with RNA interference. *Nature*. 2004;431:371–8.
- Blum M, De Robertis EM, Wallingford JB, Niehrs C. Morpholinos: antisense and sensibility. *Dev Cell*. 2015;35:145–9.
- James LC, Keeble AH, Khan Z, Rhodes DA, Trowsdale J. Structural basis for PRYSPRY-mediated tripartite motif (TRIM) protein function. *Proc Natl Acad Sci U S A*. 2007;104:6200–5.
- Mallery DL, McEwan WA, Bidgood SR, Towers GJ, Johnson CM, James LC. Antibodies mediate intracellular immunity through tripartite motif-containing 21 (TRIM21). *Proc Natl Acad Sci U S A*. 2010;107:19985–90.
- Rhodes DA, Isenberg DA. TRIM21 and the function of antibodies inside cells. *Trends Immunol*. 2017;38:916–26.
- Clift D, McEwan WA, Labzin LI, Konieczny V, Mogessie B, James LC, Schuh M. A method for the acute and rapid degradation of endogenous proteins. *Cell*. 2017;171:1692–1706.e1618.
- Schmitt C, von Kobbe C, Bachi A, Pante N, Rodrigues JP, Boscheron C, Rigaut G, Wilm M, Seraphin B, Carmo-Fonseca M, Izaurralde E. Dbp5, a DEAD-box protein required for mRNA export, is recruited to the cytoplasmic fibrils of nuclear pore complex via a conserved interaction with CAN/Nup159p. *EMBO J*. 1999;18:4332–47.
- Gross T, Siepmann A, Sturm D, Windgassen M, Scarcelli JJ, Seedorf M, Cole CN, Krebber H. The DEAD-box RNA helicase Dbp5 functions in translation termination. *Science*. 2007;315:646–9.
- Hodroj D, Recolin B, Serhal K, Martinez S, Tsanov N, Abou Merhi R, Maiorano D. An ATR-dependent function for the Ddx19 RNA helicase in nuclear R-loop metabolism. *EMBO J*. 2017;36:1182–98.
- Jao LE, Wente SR, Chen W. Efficient multiplex biallelic zebrafish genome editing using a CRISPR nuclease system. *Proc Natl Acad Sci U S A*. 2013;110:13904–9.
- Bill BR, Petzold AM, Clark KJ, Schimmenti LA, Ekker SC. A primer for morpholino use in zebrafish. *Zebrafish*. 2009;6:69–77.
- Stainier DYR, Raz E. Guidelines for morpholino use in zebrafish. *PLoS Genet*. 2017;13:e1007000.
- Bernstein E, Caudy AA, Hammond SM, Hannon GJ. Role for a bidentate ribonuclease in the initiation step of RNA interference. *Nature*. 2001;409:363–6.
- Wienholds E, Koudijs MJ, van Eeden FJ, Cuppen E, Plasterk RH. The microRNA-producing enzyme Dicer1 is essential for zebrafish development. *Nat Genet*. 2003;35:217–8.
- Giraldez AJ, Cinalli RM, Glasner ME, Enright AJ, Thomson JM, Baskerville S, Hammond SM, Bartel DP, Schier AF. MicroRNAs regulate brain morphogenesis in zebrafish. *Science*. 2005;308:833–8.
- Lister JA, Robertson CP, Lepage T, Johnson SL, Raible DW. *nacre* encodes a zebrafish microphthalmia-related protein that regulates neural-crest-derived pigment cell fate. *Development*. 1999;126:3757–67.
- Hou L, Pavan WJ. Transcriptional and signaling regulation in neural crest stem cell-derived melanocyte development: do all roads lead to Mitf? *Cell Res*. 2008;18:1163–76.
- Dooley CM, Mongera A, Walderich B, Nusslein-Volhard C. On the embryonic origin of adult melanophores: the role of ErbB and Kit signalling in establishing melanophore stem cells in zebrafish. *Development*. 2013;140:1003–13.
- Mellgren EM, Johnson SL. A requirement for kit in embryonic zebrafish melanocyte differentiation is revealed by melanoblast delay. *Dev Genes Evol*. 2004;214:493–502.
- Ahmed ZM, Yousaf R, Lee BC, Khan SN, Lee S, Lee K, Husnain T, Rehman AU, Bonneux S, Ansar M, et al. Functional null mutations of MSR3 encoding methionine sulfoxide reductase are associated with human deafness DFNB74. *Am J Hum Genet*. 2011;88:19–29.
- Kwon TJ, Cho HJ, Kim UK, Lee E, Oh SK, Bok J, Bae YC, Yi JK, Lee JW, Ryoo ZY, et al. Methionine sulfoxide reductase B3 deficiency causes hearing loss due to stereocilia degeneration and apoptotic cell death in cochlear hair cells. *Hum Mol Genet*. 2014;23:1591–601.
- Shen X, Liu F, Wang Y, Wang H, Ma J, Xia W, Zhang J, Jiang N, Sun S, Wang X, Ma D. Down-regulation of *msr3* and destruction of normal auditory system development through hair cell apoptosis in zebrafish. *Int J Dev Biol*. 2015;59:195–203.

**Ready to submit your research? Choose BMC and benefit from:**

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

**At BMC, research is always in progress.**

Learn more [biomedcentral.com/submissions](https://biomedcentral.com/submissions)

